What is a stock summary page? Click here for an overview.
Business Description

Sorrento Therapeutics Inc
NAICS : 325414
SIC : 8731
ISIN : US83587F2020
Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History |
---|
Growth Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -56.39 | |||||
12-1 Month Momentum % | -57.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -378.56 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-Forward-EBIT | -2.7 | |||||
EV-to-Forward-Revenue | 2.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sorrento Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 61.341 | ||
EPS (TTM) (€) | -0.202 | ||
Beta | - | ||
3-Year Sharpe Ratio | 0.06 | ||
3-Year Sortino Ratio | 0.11 | ||
Volatility % | 76.35 | ||
14-Day RSI | - | ||
14-Day ATR (€) | 0.12295 | ||
20-Day SMA (€) | - | ||
12-1 Month Momentum % | -57.25 | ||
52-Week Range (€) | 0.1337 - 2.79 | ||
Shares Outstanding (Mil) | 547.88 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sorrento Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sorrento Therapeutics Inc Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Sorrento Therapeutics Inc Frequently Asked Questions
What is Sorrento Therapeutics Inc(FRA:8STN)'s stock price today?
The current price of FRA:8STN is €0.30. The 52 week high of FRA:8STN is €2.79 and 52 week low is €0.13.
When is next earnings date of Sorrento Therapeutics Inc(FRA:8STN)?
The next earnings date of Sorrento Therapeutics Inc(FRA:8STN) is 2025-05-15 Est..
Does Sorrento Therapeutics Inc(FRA:8STN) pay dividends? If so, how much?
Sorrento Therapeutics Inc(FRA:8STN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |